Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials

Critical Reviews in Oncology/Hematology

Volumn 98, Issue , 2016, Pages 180-188

  Korkmaz, Taner ^a   Seber, Selcuk ^b   Basaran, Gul ^a  

^a ACIBADEM UNIVERSITY   (Turkey)

^b NAMIK KEMAL UNIVERSITY   (Turkey)

Author keywords

Maintenance treatment; Ovarian cancer; Targeted therapy

Indexed keywords

ABAGOVOMAB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; DOXORUBICIN; ERLOTINIB; GEMCITABINE; NINTEDANIB; OLAPARIB; PACLITAXEL; PAZOPANIB; PLATINUM COMPLEX; RUCAPARIB; TAXANE DERIVATIVE; TOPOTECAN; TRABECTEDIN; TREBANANIB;

ADVANCED CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESISTANCE; CARCINOGENESIS; CLINICAL RESEARCH; DISEASE COURSE; DRUG EFFICACY; DRUG TARGETING; DRUG TREATMENT FAILURE; HUMAN; MAINTENANCE THERAPY; NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECEPTOR BLOCKING; REVIEW; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); FEMALE; MAINTENANCE CHEMOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; TUMOR RECURRENCE;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84957442410     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.10.006     Document Type: Review

References (46)

1. Aghajanian C., Blank S.V., Goff B.A., Judson P.L., Teneriello M.G., Husain A., et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 2012, 30(June (17)):2039-2045.
2. Burger R.A., Brady M.F., Bookman M.A., Fleming G.F., Monk B.J., Huang H., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 2011, 365(December (26)):2473-2483.
3. Byrne A.T., Ross L., Holash J., Nakanishi M., Hu L., Hofmann J.I., et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 2003, 9:5721-5728.
4. Coleman R.L., Brady R.F., Herzog T.J., et al. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer. Presented at: Society of Gynecologic Oncology's Annual Meeting on Women's Cancer 2015, Abstract 3.
5. Cuevas C., Francesch A. Development of yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat. Prod. Rep. 2009, 26:322-337.
6. De Placido S., Scambia G., Di Vagno G., Naglieri E., Lombardi A.V., Biamonte R., et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: multicenter Italian trials in ovarian cancer (MITO-1) randomized study. J. Clin. Oncol. 2004, 22:2635-2642.
7. du Bois A., Floquet A., Kim J.W., Rau J., Del Campo J.M., Friedlander M., et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J. Clin. Oncol. 2014, pii: JCO.2014.55.7348. [Epub ahead of print].
8. du Bois, A., Kristensen, G., Ray-Coquard, I., et al., 2013. AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-Intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer. Abstracts from the 18th International Meeting of the European Society of Gynaecological Oncology (ESGO), 19-22 October 2013, Liverpool, UK. Int. J. Gynecol. Cancer, 2013, 23(8 Suppl 1).
9. FDA approves Lynparza to treat advanced ovarian cancer, 2014. US Food and Drug Administration. (accessed 26.03.15.). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm.
10. Ferriss J.S., Java J., Burger R.A., Bookman M.A., Fleming G., Monk B.J., et al. Ascites predicts degree of treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube, and peritoneal cancers. Society of Gynecologic Oncology 45. Annual Meeting on Women's Cancer 2014.
11. Gordon A.N., Finkler N., Edwards R.P., Garcia A.A., Crozier M., Irwin D.H., et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int. J. Gynecol. Cancer 2005, 15(September-October (5)):785-792.
12. Hilberg F., Roth G.J., Krssak M., Kautschitsch S., Sommergruber W., Tontsch-Grunt U., et al. BIBF1120: triple angiokinase inhibitor with sustained receptor blockade and good anti-tumor efficacy. Cancer Res. 2008, 68:4774-4782.
13. Hirte H.W., Vidal L., Fleming G.F., Sugimoto A.K., Morgan R.J., Biagi J.J., et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. J. Clin. Oncol. 2008, 26(Suppl. 20). (Abstract 5521).
14. Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
15. Hurwitz H., Dowlati A., Savage S., Fernando N., Lasalvia S., Whitehead B., et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J. Clin. Oncol. 2011, 23(Suppl):195s. Abstract 3012. BMC Cancer. 2011 Oct 20, 11, 453. 10.1186/1471-2407-11-453.
16. Itamochi H. Targeted therapies in epithelial ovarian cancer: molecular mechanisms of action. World J. Biol. Chem. 2010, 1(July (7)):209-220.
17. Kaufman B., Shapira-Frommer R., Schmutzler R.K., Audeh M.W., Friedlander M., Balmaña J., et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 2015, 33:244-250.
18. Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 2012, 366(April (15)):1382-1392.
19. Ledermann J.A., Perren T., Raja F.A., Embleton A.C., Rustin G.J.S., Jayson G., et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. Presented at: European Cancer Congress 2013 (ECCO-ESMO-ESTRO) 2013, (Abstract no: LBA10).
20. Liu J.F., Barry W.T., Birrer M., Lee J.M., Buckanovich R.J., Fleming G.F., et al. Combination olaparib and cediranib versus olaparib alone for woman with recurrent platinum-sensitive ovarian cancer: a randomized phase 2 study. Lancet Oncol. 2014, 15(11):1207-1214. Epub 2014 Sep 10. 10.1016/S1470-2045(14)70391.
21. Markman M., Liu P.Y., Wilczynski S., Monk B., Copeland L.J., Alvarez R.D., et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 2003, 21:2460-2465.
22. Martin L.P., Schilder R.J. Management of recurrent ovarian carcinoma: current status and future directions. Semin. Oncol. 2009, 36(April (2)):112-125.
23. Matulonis U.A., Berlin S., Ivy P., Tyburski K., Krasner C., Zarwan C., et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J. Clin. Oncol. 2009, 27(33):5601-5606.
24. McNeish Iain A., Oza Amit M., Coleman Robert L., Scott Clare L., Konecny Gottfried E., Tinker Anna, et al. Results of ARIEL2: a phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. J. Clin. Oncol. 2015, 33. (suppl; abstr 5508).
25. Mesiano S., Ferrara N., Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am. J. Pathol. 1998, 153:1249-1256.
26. Monk B.J., Herzog T.J., Kaye S.B., Krasner C.N., Vermorken J.B., Muggia F.M., et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J. Clin. Oncol. 2010, 28(19):3107-3114. Epub 2010 Jun 1. 10.1200/JCO.2009.25.4037.
27. Monk B.J., Poveda A., Vergote I., Raspagliesi F., Fujiwara K., Bae D.S., et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014, pii: S1470-2045(14) 70244-X. [Epub ahead of print]. 10.1016/S1470-2045(14)70244-X.
28. Ovarian Cancer Key Statistics, American Cancer Society website. Available at: , (accessed 26.03.13.). http://www.cancer.org/Cancer/OvarianCancer/DetailedGuide/ovarian-cancer-key-statistics.
29. Oza A.M., Cook A.D., Pfisterer J., Embleton A., Ledermann J.A., Pujade-Lauraine E., et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015, 86-88. pii: S1470-2045(15) 00086-8. [Epub ahead of print]. 10.1016/s1470-2045(15)00086-8.
30. Oza A.M., Cibula D., Benzaquen A.O., Poole C., Mathijssen R.H., Sonke G.S., et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015, 16(January (1)):87-97. Epub 2014 Dec 4. 10.1016/S1470-2045(14) 71135-0.
31. Pecorelli S., Favalli G., Gadducci A., Katsaros D., Panici P.B., Carpi A., et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the after-6 protocol 1. J. Clin. Oncol. 2009, 27:4642-4648.
32. Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G., et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 2011, 365:2484-2496.
33. Pfisterer J., Weber B., Reuss A., Kimmig R., du Bois A., Wagner U., et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J. Natl. Cancer Inst. 2006, 98(August (15)):1036-1045.
34. Piccart M.J., Floquet A., Scarfone G., Willemse P.H., Emerich J., Vergote I., et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int. J. Gynecol. Cancer 2003, 13(Suppl. 2):196-203.
35. Poveda A., Vergote I., Tjulandin S., Kong B., Roy M., Chan S., et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann. Oncol. 2011, 22(January (1)):39-48.
36. Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 2014, 32(May (13)):1302-1308.
37. Reinartz S., Köhler S., Schlebusch H., Krista K., Giffels P., Renke K., et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin. Cancer Res. 2004, 10:1580-1587.
38. Sabbatini P., Dupont J., Aghajanian C., Derosa F., Poynor E., Anderson S., et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin. Can. Res. 2006, 12(September (18)):5503-5510.
39. Sabbatini P., Harter P., Scambia G., Sehouli J., Meier W., Wimberger P., et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study. J. Clin. Oncol. 2013, 31(April (12)):1554-1561.
40. Shaw D., Clamp A., Jayson G.C. Angiogenesis as a target for the treatment of ovarian cancer. Curr. Opin. Oncol. 2013, 25:558-565.
41. Smolle E., Taucher V., Haybaeck J. Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer Res. 2014, 34(April (4)):1553-1561.
42. Spannuth W.A., Sood A.K., Coleman R.L. Angiogenesis as a strategic target for ovarian cancer therapy. Nat. Clin. Pract. Oncol. 2008, 5(4):194-204.
43. Stockler M.R., Hilpert F., Friedlander M., King M.T., Wenzel L., Lee C.K., et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J. Clin. Oncol. 2014, 32(May (13)):1309-1316.
44. Tian C., Markman M., Zaino R., Ozols R.F., McGuire W.P., Muggia F.M., et al. CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group Study. Cancer 2009, 115(April (7)):1395-1403. 10.1002/cncr.24152.
45. Vergote I.B., Jimeno A., Joly F., Katsaros D., Coens C., Despierre E., et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study. J. Clin. Oncol. 2014, 32(February (4)):320-326.
46. Wagner U., Schlebusch H., Kohler S., Schmolling J., Grunn U., Krebs D. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125. Hybridoma 1997, 16:33-40.